Next Issue
Volume 11, 06
Previous Issue
Volume 11, 04
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.4
Journals
Cardiovascular Medicine
Volume 11
Issue 5
cardiovascmed-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 11, Issue 5 (05 2008) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
7 pages, 231 KB  
Communication
European National Society Cardiovascular Journals
by Fernando Alfonso, Giuseppe Ambrosio, Fausto J. Pinto, Ernst E. Van der Wall, Karlen Adamyan, Eduard Apetrei, Jean-Yves Artigou, Halima Benjelloun, Michael Böhm, Massimo Chiariello, Ariel Cohen, Hugo Ector, Joseph Elias, Eckart Fleck, Mohamed Hamed, Habib Haouala, Gerd Heusch, Christer Höglund, Kurt Huber, Mario Ivanusa, Moufid Jokhadar, Gabriel Kamensky, Miran F. Kenda, Rainer Klawki, Anesti Kondili, Piotr Kulakowski, Aleksandras Laucevicius, Alexandras Laucevicius, René Lerch, Thomas F. Lüscher, Victor A. Lusov, Izet Masic, Pirjo Mustonen, Djamaleddine Nibouche, Velibor Obradovic, Rafael G. Oganov, Olaf Rødevand, Mamanti Rogava, Vedat Sansoy, Valentin Shumakov, Vladimír Stanek,, Christodoulos Stefanadis, Rumiana Tarnovska, József Tenczer, Adam Timmis, Panos Vardas and Jørgen Videbækadd Show full author list remove Hide full author list
Cardiovasc. Med. 2008, 11(5), 170; https://doi.org/10.4414/cvm.2008.01329 - 23 May 2008
Viewed by 42
Abstract
Cardiovascular scientific production in Europe is growing both in quantity and quality [...] Full article
2 pages, 453 KB  
Interesting Images
Low Dose Hybrid Cardiac Imaging in a 61-Year-Old Male With Atypical Angina Pectoris1
by Lars Husmann, Ines Valenta, Oliver Gaemperli, Christophe A. Wyss and Philipp A. Kaufmann
Cardiovasc. Med. 2008, 11(5), 168; https://doi.org/10.4414/cvm.2008.01327 - 23 May 2008
Viewed by 46
Abstract
A 61-year-old male patient with hypertension and dyslipidaemia reported recurrend episodes of chest discomfort at peak performance during bicycle exercise but also at rest and at night [...] Full article
►▼ Show Figures

Figure 1

2 pages, 1285 KB  
Interesting Images
Regular Wide QRS Tachycardia Complicating Treatment for Atrial Fibrillation
by Jens Seiler, Joseph C. Lee and Kurt C. Roberts-Thomson
Cardiovasc. Med. 2008, 11(5), 166; https://doi.org/10.4414/cvm.2008.01328 - 23 May 2008
Viewed by 38
Abstract
This 46-year-old gentleman presented with palpitations [...] Full article
►▼ Show Figures

Figure 1

6 pages, 564 KB  
Editorial
Extended Release (ER)-Nikotinsäure1 in Kombination mit Laropiprant (einem Prostaglandin-D2-Antagonist): eine neue Alternative bei der Behandlung von Patienten mit tiefem HDL-Cholesterin?
by Giorgio Noseda
Cardiovasc. Med. 2008, 11(5), 160; https://doi.org/10.4414/cvm.2008.01332 - 23 May 2008
Viewed by 52
Abstract
Nicotinic acid was discovered more than 50 years ago and is a very effective drug. It lowers the levels of all atherogenic lipoproteins – VLDL and LDL, as well as Lp(a) – and in addition it raises more than any other drug the [...] Read more.
Nicotinic acid was discovered more than 50 years ago and is a very effective drug. It lowers the levels of all atherogenic lipoproteins – VLDL and LDL, as well as Lp(a) – and in addition it raises more than any other drug the levels of the protective HDL lipoproteins. Trials have shown that treatment with nicotinic acid reduces progression of atherosclerosis and clinical events and mortality from coronary heart disease. An “extended release” (ER) formulation of nicotinic acid was developed in the hope of diminishing the flush, which is not completely absent, although less frequent and intense, and therefore limiting its use. Co-administration of laropiprant, a prostaglandin D2 receptor subtype 1 antagonist, with ERnicotinic acid significantly lowers flushing symptom scores. The combination of statin lowering LDL with this potent HDL-increasing drug is very promising in treating dyslipidaemia and in the prevention and treatment of atherosclerosis. Full article
►▼ Show Figures

Figure 1

3 pages, 529 KB  
Case Report
Massive Pericardial Effusion: Two Rare Aetiologies in One Patient
by Michael Mutter and Thomas Brack
Cardiovasc. Med. 2008, 11(5), 157; https://doi.org/10.4414/cvm.2008.01330 (registering DOI) - 23 May 2008
Viewed by 45
Abstract
We present the case of a 64-year-old, immunocompetent woman with untreated hypothyroidism, who was admitted with massive pericardial effusion. She had no clinical signs or echocardiographic evidence of pericardial tamponade. To our surprise, cultures of pericardial fluid grew salmonella enteritidis. Hypothyroidism is a [...] Read more.
We present the case of a 64-year-old, immunocompetent woman with untreated hypothyroidism, who was admitted with massive pericardial effusion. She had no clinical signs or echocardiographic evidence of pericardial tamponade. To our surprise, cultures of pericardial fluid grew salmonella enteritidis. Hypothyroidism is a known, but rare cause of pericardial effusion. Due to its insidious onset and slow fluid accumulation, it may develop unnoticed by clinicians. Pericardial infection with nontyphoidal salmonella is an extremely exceptional finding in immunocompetent subjects. Because preexisting pericardial fluid acts as a culture medium, it might rather be the result of superinfection of preexisting pericardial effusion during bacteraemia than primary salmonella pericarditis. Full article
►▼ Show Figures

Figure 1

4 pages, 314 KB  
Editorial
LDL-Cholesterin: Tiefer Ist Besser
by Walter F. Riesen
Cardiovasc. Med. 2008, 11(5), 153; https://doi.org/10.4414/cvm.2008.01331 - 23 May 2008
Viewed by 42
Abstract
Epidemiological studies indicate that low levels of LDL-cholesterol (below 1.8 mmol/l) are associated with a lower incidence of cardiovascular events and that such levels are physiological. LDL-cholesterol lowering by statins at standard dosage leaves a residual cardiovascular risk of more than 50%. Intensive [...] Read more.
Epidemiological studies indicate that low levels of LDL-cholesterol (below 1.8 mmol/l) are associated with a lower incidence of cardiovascular events and that such levels are physiological. LDL-cholesterol lowering by statins at standard dosage leaves a residual cardiovascular risk of more than 50%. Intensive cholesterol lowering with statins allows a significantly greater benefit in the prevention of fatal cardiovascular events and of stroke with a trend to lowering cardiovascular mortality. Considering an intensive statin therapy, safety aspects should be kept in mind. Higher statin doses are associated with increased undesired effects. In patients under polymedication potential interactions with high statin doses should be considered. LDL-cholesterol lowering trials with statins indicate, that there is no plateau of a LDL-cholesterol level, below which there would be no further benefit from LDL-cholesterol lowering. These studies rather indicate that lower is better. Full article
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Previous Issue
Next Issue
Back to TopTop